EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

Safety and Efficacy of DTX401 , an AAV8 ‐Mediated Liver‐Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a ( GSDIa )

David A Weinstein iD, Terry G Derks, David F Rodriguez-Buritica, Ayesha Ahmad, María-Luz Couce, John J Mitchell, Rebecca Riba-Wolman, Malaya Mount, Julieta Bonvin Sallago, Katalin M Ross, Melanie M van der Klauw, Foekje de Boer und 7 weitere

Journal of Inherited Metabolic Disease · 2025

DOI: 10.1002/jimd.70014 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von David A Weinstein und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Connecticut, Farmington, Connecticut, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Glycogen Storage Disease Type I, Dependovirus, Liver. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ultragenyx Pharmaceutical Inc, Ultragenyx Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glycogen storage disease type Ia (GSDIa) is a rare, life‐threatening, inherited carbohydrate metabolism disorder caused by glucose‐6‐phosphatase (G6Pase) deficiency, which is essential for glycogenolysis and gluconeogenesis. GSDIa management includes a strict medically prescribed diet that typically includes daily uncooked cornstarch doses, including overnight, to maintain euglycemia. DTX401 is an investigational adeno‐associated virus serotype 8 vector expressing the human G6PC1 gene that encodes G6Pase. This open‐label, phase 1/2, dose‐escalation, 52‐week gene therapy trial evaluated the safety and efficacy of a single DTX401 infusion in 12 adults with GSDIa (ClinicalTrials.gov Identifier: NCT03517085). Three participants in Cohort 1 received DTX401 2.0 × 10 12 genome copies (GC)/kg, and three participants each in Cohorts 2, 3, and 4 received 6.0 × 10 12 GC/kg. Corticosteroids were administered to mitigate vector‑induced inflammatory response. All participants experienced a treatment‐emergent adverse event (TEAE) and a related TEAE. No participant experienced a dose‐limiting toxicity, TEAE leading to study discontinuation, TEAE leading to death, or serious treatment‐related TEAE. Mean (SD) time to hypoglycemia in minutes/gram of carbohydrate during a controlled fasting challenge was 5.0 (1.6) at baseline and 6.9 (2.7) at Week 52, a mean (SD) increase of 46% (72%). Mean total daily cornstarch intake was 284 g at baseline and 85 g at Week 52 in the 10 participants with available values at both time points, a mean (SD) total daily cornstarch intake reduction of 68% (20%); p < 0.001. DTX401 showed a favorable safety and efficacy profile at Week 52. Participants in all cohorts showed significant cornstarch need reductions from baseline to Week 52.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyGlycogen Storage Disease Type IDependovirusLiverGlucose-6-PhosphataseHumansAdultMaleFemaleMiddle AgedGenetic VectorsYoung AdultTreatment OutcomeAdolescent

Stichwörter der Autor:innen

DTX401GSDGSDIagene therapyglycogen storage disease

Substanzen

Glucose-6-Phosphatase

Autor:innen und Institutionen

  • Department of Pediatrics, University of Connecticut, Farmington, Connecticut, USA.
  • Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Department of Pediatrics, Division of Medical Genetics, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth Houston) and Children's Memorial Hermann Hospital, Houston, Texas, US…
  • University of Michigan, Ann Arbor, Michigan, USA.
  • University Clinical Hospital of Santiago de Compostela, IDIS, CIBERER, Santiago de Compostela, Spain.
  • Montreal Children's Hospital, Montreal, Quebec, Canada.

ORCID-Profile: David A Weinstein

Förderung

  • Ultragenyx Pharmaceutical Inc
  • Ultragenyx Pharmaceutical

Zitieren

APA

Weinstein, D. A., Derks, T. G., Rodriguez-Buritica, D. F., Ahmad, A., Couce, M. L., Mitchell, J. J., Riba-Wolman, R., Mount, M., Sallago, J. B., Ross, K. M., van der Klauw, M. M., de Boer, F., van der Schaaf, C., Saavedra, H., Martínez-Olmos, M., Atanga, E., Hosseini, A., Mitragotri, D., & Crombez, E. (2025). Safety and Efficacy of DTX401 , an AAV8 ‐Mediated Liver‐Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a ( GSDIa ). Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70014

Vancouver

Weinstein DA, Derks TG, Rodriguez-Buritica DF, Ahmad A, Couce ML, Mitchell JJ, et al. Safety and Efficacy of DTX401 , an AAV8 ‐Mediated Liver‐Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a ( GSDIa ). Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70014

BibTeX
@article{Weinstein2025,
  author = {Weinstein, David A and Derks, Terry G and Rodriguez-Buritica, David F and Ahmad, Ayesha and Couce, María-Luz and Mitchell, John J and Riba-Wolman, Rebecca and Mount, Malaya and Sallago, Julieta Bonvin and Ross, Katalin M and van der Klauw, Melanie M and de Boer, Foekje and van der Schaaf, Caroline and Saavedra, Heather and Martínez-Olmos, Miguel and Atanga, Elvis and Hosseini, Asad and Mitragotri, Deepali and Crombez, Eric},
  title = {Safety and Efficacy of DTX401 , an AAV8 ‐Mediated Liver‐Directed Gene Therapy, in Adults With Glycogen Storage Disease Type I a ( GSDIa )},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  doi = {10.1002/jimd.70014}
}
Kostenlos starten →